128 related articles for article (PubMed ID: 35764097)
21. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
[TBL] [Abstract][Full Text] [Related]
22. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
23. Assessment of Risk of Hereditary Predisposition in Patients With Melanoma and/or Mesothelioma and Renal Neoplasia.
Gupta S; Erickson LA; Lohse CM; Shen W; Pitel BA; Knight SM; Halling KC; Herrera-Hernandez L; Boorjian SA; Thompson RH; Leibovich BC; Jimenez RE; Cheville JC
JAMA Netw Open; 2021 Nov; 4(11):e2132615. PubMed ID: 34767027
[TBL] [Abstract][Full Text] [Related]
24. Trans-ethnic variation in germline variants of patients with renal cell carcinoma.
Abou Alaiwi S; Nassar AH; Adib E; Groha SM; Akl EW; McGregor BA; Esplin ED; Yang S; Hatchell K; Fusaro V; Nielsen S; Kwiatkowski DJ; Sonpavde GP; Pomerantz M; Garber JE; Freedman ML; Rana HQ; Gusev A; Choueiri TK
Cell Rep; 2021 Mar; 34(13):108926. PubMed ID: 33789101
[TBL] [Abstract][Full Text] [Related]
25. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.
Liu N; Huang D; Cheng X; Chong Y; Wang W; Gan W; Guo H
Urol Oncol; 2017 Aug; 35(8):530.e1-530.e6. PubMed ID: 28408296
[TBL] [Abstract][Full Text] [Related]
26. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
Kroeger N; Xie W; Lee JL; Bjarnason GA; Knox JJ; Mackenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Kollmannsberger CK; Tan MH; North SA; Rini BI; Choueiri TK; Heng DY
Cancer; 2013 Aug; 119(16):2999-3006. PubMed ID: 23696129
[TBL] [Abstract][Full Text] [Related]
27. Concomitance of Polymorphisms in Glutathione Transferase Omega Genes Is Associated with Risk of Clear Cell Renal Cell Carcinoma.
Radic TM; Coric VM; Pljesa-Ercegovac MS; Basta-Jovanovic GM; Radojevic-Skodric SM; Dragicevic DP; Matic MG; Bogdanovic LM; Dzamic ZM; Simic TP; Savic-Radojevic AR
Tohoku J Exp Med; 2018 Sep; 246(1):35-44. PubMed ID: 30224590
[TBL] [Abstract][Full Text] [Related]
28. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features.
Kotecha RR; Knezevic A; Arora K; Bandlamudi C; Kuo F; Carlo MI; Fitzgerald KN; Feldman DR; Shah NJ; Reznik E; Hakimi AA; Carrot-Zhang J; Mandelker D; Berger M; Lee CH; Motzer RJ; Voss MH
Cancer; 2024 Mar; 130(5):692-701. PubMed ID: 37864521
[TBL] [Abstract][Full Text] [Related]
29. Pseudocapsule of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion: a clue for tumor enucleation?
Cheng X; He J; Gan W; Fan X; Yang J; Zhu B; Guo H
Int J Clin Exp Pathol; 2015; 8(5):5403-10. PubMed ID: 26191243
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
Zarrabi K; Walzer E; Zibelman M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359554
[TBL] [Abstract][Full Text] [Related]
31. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
32. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
33. CTLA-4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population--a prospective study.
Tupikowski K; Partyka A; Kolodziej A; Dembowski J; Debinski P; Halon A; Zdrojowy R; Frydecka I; Karabon L
Tissue Antigens; 2015 Nov; 86(5):353-61. PubMed ID: 26403483
[TBL] [Abstract][Full Text] [Related]
34. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes.
Woodward ER; Clifford SC; Astuti D; Affara NA; Maher ER
J Med Genet; 2000 May; 37(5):348-53. PubMed ID: 10807693
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.
Chahoud J; Msaouel P; Campbell MT; Bathala T; Xiao L; Gao J; Zurita AJ; Shah AY; Jonasch E; Sharma P; Tannir NM
Oncologist; 2020 Mar; 25(3):252-258. PubMed ID: 32162795
[TBL] [Abstract][Full Text] [Related]
36. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
Bergmann L; Weber S; Hartmann A; Ahrens M
Expert Rev Anticancer Ther; 2021 Nov; 21(11):1273-1286. PubMed ID: 34291700
[No Abstract] [Full Text] [Related]
37. 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness.
Eckel-Passow JE; Yan H; Kosel ML; Serie D; Decker PA; Jenkins RB; Costello B; Leibovich B; Ho TH; Parker A
BMC Urol; 2020 Oct; 20(1):173. PubMed ID: 33121461
[TBL] [Abstract][Full Text] [Related]
38. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
39. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.
Malinoc A; Sullivan M; Wiech T; Schmid KW; Jilg C; Straeter J; Deger S; Hoffmann MM; Bosse A; Rasp G; Eng C; Neumann HP
Endocr Relat Cancer; 2012 Jun; 19(3):283-90. PubMed ID: 22351710
[TBL] [Abstract][Full Text] [Related]
40. Family history and risk of renal cell carcinoma.
Gago-Dominguez M; Yuan JM; Castelao JE; Ross RK; Yu MC
Cancer Epidemiol Biomarkers Prev; 2001 Sep; 10(9):1001-4. PubMed ID: 11535554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
